Understanding and addressing rejection of personalized cancer risk information

了解并解决拒绝个性化癌症风险信息的问题

• 批准号: 10639183
• 负责人: Laura D. Scherer
• 金额: $ 66.05万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-08-01 至 2028-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10639183
• 关键词: Address; Affect; Age; American Cancer Society; Area; Assessment tool; Behavior; Behavioral; Breast Cancer Detection; Breast Cancer Risk Factor; Cancer Control; Cardiovascular Diseases; Colon; Communication; Communication Methods; Communities; Comprehension; Decision Making; Demographic Factors; Development; Diagnosis; Disease; Evaluation; Family history of; Feedback; Fostering; Future; Goals; Guidelines; Harm Reduction; Health; Health Services; High Risk Woman; Individual; Interview; Knowledge; Longitudinal Studies; Longitudinal Surveys; Lung; Maintenance; Malignant Neoplasms; Mammographic screening; Mammography; Medical; Medical History; Medicine; Nature; Outcome; Patient Care; Patients; Persons; Prevention; Preventive Medicine; Process; Process Assessment; Prostate; Psychological Factors; Race; Randomized; Recommendation; Research; Risk; Risk Assessment; Risk Estimate; Risk Factors; Risk Marker; Risk Reduction; Sampling; Science; Screening for cancer; Surveys; Testing; Translating; United States Preventative Services Task Force; Woman; Work; cancer risk; clinical application; clinical practice; cognitive interview; distrust; experimental study; high risk; improved; individual patient; information seeking behavior; patient screening; precision cancer prevention; precision medicine; precision oncology; psychologic; risk minimization; risk prediction model; risk stratification; screening; screening guidelines; tailored health care; theories

PROJECT SUMMARY/ABSTRACT We are entering an era of precision medicine for cancer screening in which screening initiation and maintenance is based on personal risk estimates that incorporate multiple risk factors, with the goal of maximizing screening benefits and minimizing the harms. One increasingly common clinical application involves using cancer risk prediction models to inform which patients are screened, how often they are screened, and at which ages screening occurs (i.e., risk-based screening). For breast cancer screening with mammography, the U.S. Preventive Services Task Force recommends informed choice about when to begin regular screening for women age 40-49. Making an informed choice means determining whether, for an individual woman, the likelihood of receiving a screening benefit outweighs the likelihood of harms such as false positive results and overdiagnosis. A critical component of informed choice is a woman’s personal cancer risk, because the expected benefit of screening depends on a woman’s personal risk of breast cancer, with women at lower risk being less likely to benefit and more likely to be harmed than women at higher risk. Hence, incorporating informed choice into the mammography screening decision-making process means that women are asked to make decisions about screening based on their personalized breast cancer risk estimates. However, a critical barrier to implementing guideline-recommended informed choice in mammograpy screening is that many people reject that their risk estimate is true for them personally, a phenomenon we refer to as risk rejection. While previous research has focused on risk comprehension as a high-impact target for improving medical decisions, we argue that risk rejection is also a high impact target for improving health decision making because people who reject their risk are unlikely to make health decisions based on that risk estimate, even when they comprehend the estimate. An estimated 1-in-4 women believe that their breast cancer risk estimate is not accurate for them, and little is known about why, or the implications for screening decisions. In Aim 1, we will use a longitudinal survey to understand the scientific nature of risk rejection. Aim 1a will identify key demographic and psychological predictors of risk rejection. In particular, we will test 4 theory-informed hypotheses about why people reject their risk: motivated reasoning, prior knowledge, distrust, and lack of perceived personal relevance. Aim 1b will identify the impact of risk rejection on risk-concordant screening behavior. In Aim 2, we will conduct interviews and use experiments to identify communication strategies to reduce risk rejection. These studies will provide a comprehensive understanding of a phenomenon – risk rejection – which, if not addressed, will impede the implementation of informed patient choice in breast cancer screening and personalized, risk-based medicine more broadly.

项目总结/文摘